Introduction
Mitral valve regurgitation (MR) is the second most common valve disease in Europe.
1 The classification and recommendations for intervention in MR are defined in the Clinical Practice
Guidelines of the European Society of Cardiology (ESC) and the American College of Cardiology and American Heart Association (ACC/AHA) Task Force. 2, 3 Surgical mitral valve repair outcomes and long-term follow-up of patients are still lacking. [3] [4] [5] [6] As a significant number of patients (49%) 7 The MitraClip System (Abbott Vascular-Structural Heart, Menlo Park, California, United States) is the only approved system in Europe for beating-heart endovascular transcatheter MVR. In this technique, both mitral valve leaflets are attached with one or more clips, resulting in a so-called "double-orifice mitral valve". Despite the lack of scientific evidence of proven benefit of the MitraClip procedure, a steady increase in its use has been seen in Germany and Europe. According to Federal Statistical Office registered data (provided on request), 51 endovascular MVR procedures were performed in 2008, whereas in 2010, 809 procedures were performed, corresponding to an increase of 1,500%. The age distribution (<75 years) seems to suggest that the procedure was not restricted to only elderly and high-risk patients.
Aims of the Study
The aims of this study were to perform a systematic literature review to evaluate (1) whether there are any indication criteria, process and structural requirements, or scientific society and institutional guidelines for the use of the MitraClip System, and (2) to establish whether there is an evidence base demonstrating clinical benefit of the MitraClip System.
Method
A systematic literature search was performed and analyzed with evidence criteria in the following databases: PubMed/ Medline, Cochrane Library, and Health Technology Assessment of the German Institute of Medical Documentation and Information. In addition, a general topic-based search was performed using the Google search engine, and a manual search for publications was performed. The search was limited by the following criteria: meta-analyses, controlled clinical trial, humans, randomized controlled trial (RCT), comparative study, review, systematic review, practice guidelines, guidelines, and 10-year period.
Results
A total of 1,395 search results were obtained, and after checking for duplicates and relevance a total of 223 publications remained for evaluation. Of the 1,395 publications, 42 were included to answer the questions. In March 2013, the German Cardiac Society (DGK) together with the German Society of Thoracic and Cardiac-and Vascular Surgery (DGTHG) published a consensus statement and requirements for the treatment of mitral regurgitation and transcatheter treatment with the MitraClip System. 8, 9 No further consensus statements or requirements/guidelines from relevant European and international scientific societies or health-care institutions were found. Because of the lack of evidence and controlled studies, the presented results with respect to indications, for the procedure, and structural and process requirements, are also based on data extracted from noncontrolled (NC) studies. The publications included in the review and analysis are presented in ►Table 1.
Scientific Evidence Base for the Use of the MitraClip System
In the only RCT, the EVEREST II study (Endovascular Valve Edge-to-Edge Repair Study), the MitraClip (MitraClip group) was compared with conventional oMVS (oMVS group) for the first time in 279 patients. 10 The EVEREST II study, funded by Abbott Vascular, is a multicenter, prospective, single-arm study to evaluate the feasibility, safety, and effectiveness of the MitraClip System with a 30-day, 6-month, 12-month, and 5-year clinical follow-up (Clinicaltrials.gov number NCT00209339). The primary end point for effectiveness at 12 months was absence of death, reoperation due to mitral valve dysfunction, or MR >þ2.
Procedural success was between 80 and 100%, and reduction of MR to <þ2 at 30 days was 77% in the MitraClip group versus 100% in the oMVS group. This was consistent with the success rates seen in the NC studies, which showed a reduction in MR in 60 to 100% of the patients. The need for a second oMVS procedure in EVEREST II was 5.7% in the MitraClip group versus 0% in the oMVS-group at 30 days, and 20 versus 4% at 12 months. The NC studies also showed reoperation rates between 6 and 22.7%. After 2 years, the reoperation rates were 22 and 4% for the MitraClip group and oMVS group, respectively. New York Heart Association (NYHA) class and quality of life were improved within the first 30 days, but there was no difference after 12 months between the two groups in the RCT. The NC studies showed an improvement in NYHA class in 60 to 100% of the patients after 12 months. The major adverse event (MAE) rate was significantly lower at 30 days in the MitraClip group compared with oMVS group. NC studies showed MAE rates between 3 and 26% in patients treated with MitraClip, and therefore, the superiority of the clipping procedure with respect to MAE remains to be proven. With respect to mortality at 30 days (1%) and at 12-month and 24-month follow-up (7%), there was no difference between the two groups in the RCT. NC studies showed mortality rates between 0 and 15% at 30 days and between 7 and 24% at 12 months after the MitraClip procedure. The MitraClip procedure is less invasive than oMVS. To date, no data about cost effectiveness are available, although it has been suggested that costs might be reduced using transcatheter interventions (TIs) such as MitraClip because of shorter hospital stays and a reduction in hospital admissions.
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Measures for Quality Assurance
Despite the lack of evidence, poor quality of the majority of the publications, and lack of international guidelines, indication criteria, and structural and procedural standards could be extracted from the current literature. The extracted requirements are shown in ►Tables 2-4. Until now, there have been no systematic studies evaluating the evidence regarding the safety, efficacy, and cost-effectiveness of the MitraClip System compared with oMVS. In the only published RCT no superiority of MitraClip is demonstrated. Although quality of life and NYHA class were significantly improved in the first 12 months postprocedure, there was no difference to oMVS. There were also no significant differences with respect to MAE and mortality rate. The high reoperation rate after the MitraClip procedure of 20% at 12 months, missing data on long-term follow-up and outcomes, and inadequate reporting of the number and nature of MAEs also cannot be ignored.
Recommendations Concerning Indication Criteria
There are no clear, scientifically based, indication criteria for the use of the MitraClip System. The literature suggests that there may be a benefit for "inoperable" or "high-risk" patients with severe MR (3þ or 4 þ ) with clear indication for oMVS (similar to the definition of inoperability and high risk in is currently the main indication for the MitraClip System; in FMR, there are no structural alterations of the mitral leaflets so optimal clip placement is anatomically possible. The decision for treatment should be taken according to similar guidelines established for the TAVI procedure, namely, in a multidisciplinary heart team which includes an interventional cardiologist, a cardiac surgeon, and an echocardiography specialist (►Table 3).
Recommendations for Structural, Procedural, and Documentation Standards
This literature does not provide the scientific evidence base for the structural, procedural, or documentation standards that should be adopted for MitraClip use. Before MitraClip treatment, 12 medications need to be optimized and, if applicable, cardiac resynchronization therapy should be performed. 13 The presence of a catheter laboratory and/or a hybrid operation room, and transesophageal echocardiography (TEE), are minimal requirements (►Table 3). Many authors recommend three-dimensional TEE, a specialized echocardiography laboratory, and an echocardiographic specialist with specialist expertise in the MitraClip System and/or expertise in MVR (►Tables 3 and 4). The MitraClip procedure should be performed only in an interdisciplinary heart team in hospitals with departments of cardiac surgery and cardio-anesthesia that possess technical equipment for treatment of intraprocedural complications using extracorporeal circulation (ECC). A special focus is placed on the demand for an interventional cardiologist with specialist expertise in transseptal puncture. A further recommendation is the inclusion of the patients treated with the MitraClip System in a scientific registry and controlled clinical studies, the German aortic valve registry could serve as a model for this (►Table 4).
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Further Areas of Research
Before any further expansion of the use of the MitraClip procedure further data about indications and long-term results are needed to enable valid comparison with "goldstandard" oMVS. In the early postoperative course, the MAE Table 2 Indication criteria and contraindications for the use of the MitraClip system
Certain indications (patients benefit from treatment) References
Symptomatic/asymptomatic MR 3þ to 4þ with reduced LVEF Functional MR [8] [9] [10] [11] [12] 19, 29, 31, 35, 36, 39, 40, 47, 48 Multimorbidity, high-risk patient, contraindication for oMVS: log EuroScore > 20% and/or STS-Score >10% 11, 13, 14, 19, 21, 24, 26, 31, 35, 42, 43, 48, 49 AHA/ASC/ESC criteria for oMVS fulfilled [10] [11] [12] 20, 21, 38, 40, 43, 45, 47, 50 Previous cardiac surgery 13, 14, 20, 26, 40, 45 Echocardiographic criteria for treatment with MitraClip system fulfilled 8, 9, 19, 32, 33 Chest radiation/porcelain aorta 8, 9, 16, 26, 45, 51 Possible indications
Symptomatic or asymptomatic MR 3þ to 4þ with normal LVEF and above described risk factors Degenerative MVR (DMI) 11,13,14,19,21,24,31,35,42,43,48,49 8,9 Ultima ratio after failed oMVS 8, 9, 23 Younger patients (< 75 y) as a bridge to cardiac surgery or for whom life-long anticoagulant medications would be unacceptable (women before childbearing or pregnant) rate is an essential criterion, in particular bleeding, although neurological and renal complications should also be evaluated. Furthermore, critical points for evaluation are reoperation and reintervention rates in the early postoperative period, and during long-term follow-up. A clear definition of highrisk patients is missing, although the TAVI definitions might provide a framework for future guidelines. 17 So far, no superiority in cost effectiveness has been shown for the MitraClip System.
Perspectives
Currently, there do appear to be hazards associated with MitraClip therapy. However, the MitraClip procedure has the potential to be a valid treatment option for selected patients with severe MR. In particular, based on current evidence, high-risk symptomatic, or otherwise inoperable patients with severe MR seem to be the best candidates for the MitraClip System, whenever echocardiographic criteria of eligibility are met. From the current results, no conclusions can be drawn on what the routine indications are for the MitraClip System. It is also of concern that there is no obligate or statutory regulation on necessity for multidisciplinary care, with involvement of a cardiac surgeon and cardiac anesthesiologist. The MitraClip device should be used only in a small number of centers, with specialized surgical and interventional experience and training. It is believed that other innovative interventional procedures are already in use for treatment of MR, rules and recommendations need to be applicable and available at an early stage of implementation.
Conclusions
Analogous to the widely used TAVI procedures, treatment with the MitraClip System should be restricted to patients in which oMVS is contraindicated, or where there is very high perioperative risk (such as Society of Thoracic Surgeons score > 10 or EuroScore > 20, age > 75 years) in selected cases. Specific risk scores and models should be developed for the implementation of novel products for transcatheter interventions.
The majority of studies are in agreement that a "heart team" approach, in which a cardiac surgeon, an interventional cardiologist and an echocardiographic specialist actively participate in the procedure. Participation in a national scientific-based registry is strongly recommended. Further results from prospective, RCTs are needed to determine device durability and the ideal candidates for the procedure. 8,9,11,12,19,22,27 32,37,43,45,49,51 Hybrid operation room (Cardiac catheter laboratory/fluoroscopy) (mobile X-ray with C-arm not sufficient) 8, 9, 12, 19, 22, 27, 43, 49 Cardiac surgery on-site (to handle potential intraprocedural complications) 49, 52 Intensive care unit (24 h monitoring) 3, 19, 22, 27, 45, 49 Anesthesiologist with cardiac expertise 3, 19, 22, 27, 45, 49 
Personnel resources
Interventional cardiologist (expertise in transseptal puncture) 8, 9, 13, 19, 45, 47, 49, 52 Special echocardiography training (Mitral valve repair, transseptal puncture) 3, 8, 9, 19, 45, 49, 52 Heart team-multidisciplinary (cardiac surgeon and cardiologist) 3, 8, 9, 11, 19, 49, 52 Abbreviations: TEE, transesophageal echocardiography; TTE, transthoracic echocardiography; 3D, three-dimensional. Before first implantation specific training of all participants and technical support of the manufacture 45, 49, 52 Performed by interdisciplinary heart team (cardiologist, interventionell cardiologist (with expertise in trans-septal puncture), cardiac surgeon, anesthesiologist with cardiac expertise) 11, 19, 45, 49, 53 Echocardiologist with special expertise and training in MVR and cardiac interventional procedures, special training for MitraClip intervention, special expertise in TEE and 3D TEE 8, 9, 11, 19, 25, 32, 34, 45, 49, 52 Participation in registry or clinical trial 11, 14, 15, 52 Abbreviations: TEE, transesophageal echocardiography; 3D, threedimensional.
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